SAN DIEGO, June 14, 2017 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced the
appointment of Jennifer Jarrett to
the Company's Board of Directors. Ms. Jarrett has over 20
years of experience as a senior executive and finance professional
in the life sciences industry.
"We are excited to have someone with Jennifer's financial,
business and strategic experience joining our board at such an
important time," said Tina Nova,
Chairman of the Board of Directors of Arena. "We are confident that
her vast industry insights and business development, operational
and financial expertise will be highly beneficial to Arena as we
continue to advance our promising pipeline and plan for key
clinical milestones in 2017."
Ms. Jarrett currently serves as Chief Business Officer and Chief
Financial Officer of Arcus Biosciences, a biotechnology company
developing next generation cancer immunotherapies. Prior to Arcus,
she was Chief Financial Officer of Medivation, which was acquired
by Pfizer in 2016. Before Medivation, Ms. Jarrett spent 20 years in
investment banking, most recently at Citigroup, where she ran the
firm's west coast life sciences investment banking practice, and
prior to that at Credit Suisse and Donaldson, Lufkin &
Jenrette. In 2014, she was named one of the Most Influential Women
in Bay Area Business by the San Francisco Business Times. Ms.
Jarrett received a Bachelor of Arts in economics from Dartmouth College and an MBA from Stanford Graduate
School of Business.
About Arena
Pharmaceuticals
At Arena,
we are focused on developing novel, small molecule drugs with
optimized receptor pharmacology designed to deliver broad clinical
utility across multiple therapeutic areas. Our proprietary pipeline
includes potentially first- or best-in-class programs for which we
own global commercial rights. Our three most advanced
investigational clinical programs
are ralinepag (APD811)
in Phase 2 evaluation for pulmonary arterial hypertension
(PAH), etrasimod (APD334)
in Phase 2 evaluation for multiple autoimmune indications including
ulcerative colitis (UC),
and APD371 in
Phase 2 evaluation for the treatment of pain associated
with Crohn's disease. In addition, we have collaborations
with the following pharmaceutical companies: Eisai Co., Ltd.
and Eisai
Inc. (commercial stage),
Axovant Sciences (Phase 2 candidate),
and Boehringer Ingelheim International
GmbH (preclinical
candidate).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about the significance and participation of the
appointment of Ms. Jarrett; Arena's focus, and the potential of its
programs and collaborations. For such statements, Arena
claims the protection of the Private Securities Litigation Reform
Act of 1995. Actual events or results may differ materially from
Arena's expectations. Factors that could cause actual results to
differ materially from the forward-looking statements include those
disclosed in Arena's filings with the Securities and Exchange
Commission. These forward-looking statements represent Arena's
judgment as of the time of this release. Arena disclaims any intent
or obligation to update these forward-looking statements, other
than as may be required under applicable law.
Corporate
Contact
Kevin R. Lind
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-appoints-jennifer-jarrett-to-board-of-directors-300473532.html
SOURCE Arena Pharmaceuticals, Inc.